Skip to main content

Table 2 Pegvaliase exposure

From: Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study

  Phase 2 participants (N = 80)
Treatment duration, weeks
 Mean (SD) 167.0 (111.1)
 Min, max 0.71, 370.4
Treatment duration, n (%)
  < 1 year 15 (18.8%)
  ≥ 1 to < 2 years 12 (15.0%)
  ≥ 2 to < 3 years 10 (12.5%)
  ≥ 3 to < 4 years 12 (15.0%)
  ≥ 4 years 31 (38.8%)
  1. All data from phase 2 studies are included
  2. max maximum, min minimum, SD standard deviation